ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 634
- Registration Number
- NCT00296361
Comparing Efficacy and Safety of Steroid Withdrawal With Tacrolimus and MMF With Induction in Children After Kidney Transplantation
Phase 3
Completed
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 198
- Registration Number
- NCT00296348
Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation.
- First Posted Date
- 2006-02-27
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 267
- Registration Number
- NCT00296309
Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients
Phase 2
Completed
- Conditions
- Hepatitis CLiver Transplantation
- Interventions
- Drug: TacrolimusDrug: steroids, monoclonal anti-IL2R antibody
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 138
- Registration Number
- NCT00295607
Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 627
- Registration Number
- NCT00295594
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 645
- Registration Number
- NCT00293930
A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2008-02-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 658
- Registration Number
- NCT00293917
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 658
- Registration Number
- NCT00293891
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Phase 2
Completed
- Conditions
- Hodgkin's LymphomaNon-Hodgkin's LymphomaAcute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaMyelodysplastic SyndromeAcute Myelogenous Leukemia
- Interventions
- Biological: VCL-CB01Other: Phosphate-buffered Saline (PBS)
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 112
- Registration Number
- NCT00285259
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia
Phase 3
Completed
- Conditions
- Sleep DisordersSleep Initiation and Maintenance Disorders
- Interventions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 876
- Registration Number
- NCT00283946
© Copyright 2025. All Rights Reserved by MedPath